Quality of Life Therapy for Adults With Hepatitis C Virus and Cirrhosis Awaiting Liver Transplantation
Primary Purpose
Chronic HCV
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Quality of Life Therapy
Supportive Therapy
Sponsored by
About this trial
This is an interventional other trial for Chronic HCV focused on measuring Liver Transplantation, Quality of Life, Chronic HCV, Hepatitis C Virus, Cirrhosis, Liver disease
Eligibility Criteria
Inclusion Criteria:
- Male or female patients between 21 and 70 years of age
- Diagnosis of chronic HCV
- Wait-listed for liver transplantation
- Signed informed consent
- Primary caregiver identified as spouse or domestic partner
- Resides within 60 minutes of transplant center
- MELD score < 20
Exclusion Criteria:
- Prior recipient of liver transplantation
- Prior recipient of other solid organ transplantation
- Wait-listed for combined liver-kidney transplantation
- Current substance abuse or dependency
- Currently hospitalized
- Sustained (2 or more consecutive months) MELD score less than or equal to 20
- Current recipient of psychological intervention services
- Substantial cognitive impairment (score of 23 or less on the Mini-Mental State Examination)
- Communication difficulties (speech, hearing) so substantial that they would prevent patient from participating actively in one of the interventions (determined by interviewer rating)
Sites / Locations
- Beth Israel Deaconess Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
No Intervention
Arm Label
QOLT
ST
Standard Care
Arm Description
Quality of Life Therapy (QOLT) 8 weekly individual counseling sessions.
Supportive Therapy (ST) 8 weekly individual counseling sessions
Outcomes
Primary Outcome Measures
Scores on the following measures at 12 weeks post-intervention: Quality of Life Inventory, SF-36, Liver Disease Quality of Life instrument, CDC's Activity Limitations Module HRQoL-14, Hopkins Symptom Checklist-25, POMS, and Miller Social Intimacy Scale.
Secondary Outcome Measures
Full Information
NCT ID
NCT00794911
First Posted
November 19, 2008
Last Updated
March 14, 2017
Sponsor
Beth Israel Deaconess Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT00794911
Brief Title
Quality of Life Therapy for Adults With Hepatitis C Virus and Cirrhosis Awaiting Liver Transplantation
Official Title
Quality of Life Therapy for Adults With Hepatitis C Virus and Cirrhosis Awaiting Liver Transplantation
Study Type
Interventional
2. Study Status
Record Verification Date
March 2011
Overall Recruitment Status
Completed
Study Start Date
September 2007 (undefined)
Primary Completion Date
December 2010 (Actual)
Study Completion Date
December 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beth Israel Deaconess Medical Center
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The main purpose of this study is to determine whether psychological intervention is effective in improving quality of life, mood, and relationships among adults with hepatitis C virus and cirrhosis awaiting liver transplantation.
Detailed Description
Quality of life (QOL) outcomes are important to all stakeholders in liver transplantation. For patients with end-stage liver disease, QOL is significantly compromised and more data about QOL allows them to make an informed risk-benefit analysis in deciding whether to pursue transplantation. The long-term goal of this research program is to better understand how QOL can be enhanced, to identify the mechanisms underlying QOL changes, to identify which patients benefit most from QOL intervention, and to determine whether QOL benefits can extend beyond transplantation. The objective of this research is to determine the effectiveness, feasibility and applicability of Quality of Life Therapy (QOLT) in treating adults with hepatitis C virus and cirrhosis awaiting liver transplantation. In a recent small, single-center clinical trial, we demonstrated that QOLT can improve QOL, psychological functioning, and social intimacy in patients awaiting lung transplantation. We now seek to examine whether this intervention can be effectively adapted and implemented with adults with hepatitis C virus and cirrhosis awaiting liver transplantation. The central hypothesis is that by targeting improvements in specific life domains, QOLT yields significant clinical benefits in QOL, psychological functioning, and the patient-caregiver relationship. This hypothesis is being tested by pursuing three specific aims: 1) Determine the effectiveness of QOLT; 2) Examine the differential effectiveness of QOLT by race (White, African American); and 3) Assess the feasibility of a multisite R01 application. Under the first aim, adults with hepatitis C virus and cirrhosis awaiting liver transplantation are being randomized to receive QOLT, Supportive Therapy (ST), or Standard Care (SC). Primary outcomes are changes in QOL, psychological functioning, and social intimacy at 1 and 12 weeks post-treatment. Under the second aim, the relationship between race and intervention outcomes will be closely examined. Under the third aim, attrition rates, reasons for attrition, therapist adherence to treatment protocols, and participant satisfaction ratings are being gathered to assess the need for protocol changes prior to developing a larger, multisite clinical trial R01 application. This study is innovative because it is among the first to evaluate a theoretically-driven psychological intervention to specifically improve QOL in the context of hepatitis C virus and cirrhosis and liver transplantation. The research is significant because it is expected to advance and expand understanding of how QOL can be improved in patients with hepatitis C virus and cirrhosis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic HCV
Keywords
Liver Transplantation, Quality of Life, Chronic HCV, Hepatitis C Virus, Cirrhosis, Liver disease
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
75 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
QOLT
Arm Type
Experimental
Arm Description
Quality of Life Therapy (QOLT) 8 weekly individual counseling sessions.
Arm Title
ST
Arm Type
Active Comparator
Arm Description
Supportive Therapy (ST) 8 weekly individual counseling sessions
Arm Title
Standard Care
Arm Type
No Intervention
Intervention Type
Behavioral
Intervention Name(s)
Quality of Life Therapy
Intervention Description
8 weekly individual counseling sessions
Intervention Type
Behavioral
Intervention Name(s)
Supportive Therapy
Intervention Description
8 weekly individual counseling sessions
Primary Outcome Measure Information:
Title
Scores on the following measures at 12 weeks post-intervention: Quality of Life Inventory, SF-36, Liver Disease Quality of Life instrument, CDC's Activity Limitations Module HRQoL-14, Hopkins Symptom Checklist-25, POMS, and Miller Social Intimacy Scale.
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female patients between 21 and 70 years of age
Diagnosis of chronic HCV
Wait-listed for liver transplantation
Signed informed consent
Primary caregiver identified as spouse or domestic partner
Resides within 60 minutes of transplant center
MELD score < 20
Exclusion Criteria:
Prior recipient of liver transplantation
Prior recipient of other solid organ transplantation
Wait-listed for combined liver-kidney transplantation
Current substance abuse or dependency
Currently hospitalized
Sustained (2 or more consecutive months) MELD score less than or equal to 20
Current recipient of psychological intervention services
Substantial cognitive impairment (score of 23 or less on the Mini-Mental State Examination)
Communication difficulties (speech, hearing) so substantial that they would prevent patient from participating actively in one of the interventions (determined by interviewer rating)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James R Rodrigue, Ph.D.
Organizational Affiliation
Beth Israel Deaconess Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Quality of Life Therapy for Adults With Hepatitis C Virus and Cirrhosis Awaiting Liver Transplantation
We'll reach out to this number within 24 hrs